Juan Xu

Dr. Juan Xu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
CJChenyang Jin
Chenyang Jin
YYYutong Ye
Yutong Ye
LGLongzhe Gao
Longzhe Gao
ZZZikan Zhong
Zikan Zhong
CZChangzuan Zhou
Changzuan Zhou
JXJuan Xu
Juan Xu
Myocardial infarction (MI) is currently one of the most fatal cardiovascular diseases worldwide. The screening, treatment, and prognosis of MI are top priorities for cardiovascular centers globally due to its characteristic occult onset, high lethality, and poor prognosis. MI is caused by coronary artery occlusion induced by coronary atherosclerotic plaque blockage or other factors, leading to ischemic necrosis and apoptosis of cardiomyocytes. Although significant advancements have been made in the study of cardiomyocytes at the cellular and molecular levels, RNA-binding proteins (RBPs) have not been extensively explored in the context of MI. RBPs, as key regulators coordinating cell differentiation and tissue homeostasis, exhibit specific functions in gene transcription, RNA modification and processing, and post-transcriptional gene expression. By binding to their target RNA, RBPs coordinate various RNA dynamics, including cellular metabolism, subcellular localization, and translation efficiency, thereby controlling the expression of encoded proteins. Classical RBPs, including HuR, hnRNPs, and RBM family molecules, have been identified as critical regulators in myocardial hypoxia, oxidative stress, pro-inflammatory responses, and fibrotic repair. These RBPs exert their effects by modulating key pathophysiological pathways in MI, thereby influencing specific cardiac outcomes. Additionally, specific RBPs, such as QKI and fused in sarcoma (FUS), are implicated in the apoptotic pathways activated during MI. This apoptotic pathway represents a significant molecular phenotype in MI, offering novel perspectives and insights for mitigating cardiomyocyte apoptosis and attenuating the progression of MI. Therefore, this review systematically summarizes the role of RBPs in the main pathophysiological stages of MI and explores their potential therapeutic prospects.

12 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZZzikan zhong
zikan zhong
CJChenyang Jin
Chenyang Jin
XLXudong Li
Xudong Li
LGLongzhe Gao
Longzhe Gao
YYYutong Ye
Yutong Ye
JXJuan Xu
Juan Xu
Background/Objectives: Ischemia-reperfusion injury (IRI) contributes significantly to cardiomyocyte death following myocardial infarction, largely through sustained inflammatory signaling. This study aimed to identify stress-responsive deubiquitinating enzymes involved in cardiomyocyte injury under ischemic stress. Methods: HL-1 cardiomyocytes were subjected to oxygen-glucose deprivation and reoxygenation (OGD/R), followed by transcriptomic analysis, genetic manipulation of Usp31, biochemical assessment of p65 ubiquitination, NF-κB reporter assays, and in vitro deubiquitinase activity assays using sodium tanshinone IIA sulfonate (STS). Results: Usp31 was persistently upregulated in HL-1 cardiomyocytes after OGD/R. Depletion of Usp31 improved cell viability and reduced lactate dehydrogenase (LDH) release under OGD/R conditions. Mechanistically, Usp31 stabilized p65 and supported NF-κB activation, whereas Usp31 deficiency increased p65 ubiquitination and limited NF-κB transcriptional activity. STS inhibited recombinant Usp31 enzymatic activity under the experimental conditions tested and reduced Usp31-associated NF-κB activation and cardiomyocyte injury in cellular assays. Conclusions: These findings identify Usp31 as a candidate regulator of NF-κB-associated inflammatory responses in cardiomyocytes and support STS as a pharmacological modulator of Usp31-associated signaling with potential relevance to myocardial ischemic injury.

21 August 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
LLLin Liang
Lin Liang
LLLiping Li
Liping Li
TWTong Wei
Tong Wei
XLXiaofeng Lu
Xiaofeng Lu
YLYan Liu
Yan Liu
JXJuan Xu
Juan Xu
Background: Left bundle branch area pacing (LBBAP) has emerged as a physiological pacing strategy. LBBAP has been predominantly performed using the lumen-less lead. Objectives: This study aims to explore the efficacy and safety of LBBAP performed with stylet-driven leads (SDL) via site-selective pacing catheter (SSPC) sheaths. Methods: We evaluated consecutive 79 patients undergoing LBBAP using standard stylet-driven active leads via SSPC sheaths. Pacing parameters (threshold, R-wave amplitude, impedance), QRS morphology and duration, left ventricular activation time in lead V5 and complication rates were analyzed. Postoperative measurements of lead parameters and complications were recorded at 1, 3, 6, and 12 months. Results: LBBAP was successfully achieved in 69 of the 79 patients (87.3%), with 7742 leads via SSPC sheaths, with 52 patients (65.8%) showing visible left bundle branch potentials. Mean paced QRS duration and left ventricular activation time in lead V5 were 111.1 ± 27.2 ms and 69.0 ± 11.7 ms. Intraoperative electrode parameters for SDL-LBBAP, including pacing threshold (0.8 ± 0.2 V at 0.4 ms), impedance (792.5 ± 140.7 ohms), and sensing amplitude (14.0 ± 5.9 mV), remained stable during the 12 month follow up. Intraoperative ventricular septal perforation occurred in six patients (7.6%), with no subsequent persistent ventricular septal defects. Procedural time and fluoroscopy exposure time were lower in the latter 39 patients, declining markedly as operator experience accumulated. Conclusions: The application of SDL in LBBAP is safe and feasible, with excellent success rates and stable long term electrical performance.